Comparative Pharmacology
Head-to-head clinical analysis: MECLAN versus TETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECLAN versus TETRACYCLINE HYDROCHLORIDE.
MECLAN vs TETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meclizine is an antihistamine with central anticholinergic properties. It blocks histamine H1 receptors and exerts antiemetic effects via inhibition of the vestibular system and chemoreceptor trigger zone.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
250 mg orally three times daily for 7-14 days; for sinusitis: 500 mg three times daily.
250-500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 12 hours. Maximum oral dose: 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours).
6-11 hours (prolonged to 57-120 hours in severe renal impairment; reduced in hepatic dysfunction; clinically relevant for dosing interval adjustments).
Renal excretion of unchanged drug and metabolites: ~70%; fecal/biliary: ~30%.
Renal (60% unchanged via glomerular filtration), biliary (40% as active drug and metabolites, with enterohepatic recirculation; fecal elimination of unabsorbed drug).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic